Abstract:Objectives: Cholangiocarcinoma (CCA) is the second-most common primary hepatic malignancy with an increasing incidence over the past two decades. CCA arises from the epithelial cells lining the bile ducts and can be classified as intrahepatic, perihilar, or distal based on the site of origin in the biliary tree. Surgical resection is the definitive curative therapy for early-stage intrahepatic CCA; however, only a minority of patients may be ideal surgical candidates. Percutaneous microwave ablation (MWA) is a minimally invasive procedure widely used for hepatocellular carcinoma and colorectal cancer metastases to the liver. Growing evidence suggests MWA can play a role in the management of patients with early-stage intrahepatic CCA. In this study, we aim to describe the safety and efficacy of MWA for the management of intrahepatic CCA. Material and methods: A retrospective review of patients with intrahepatic CCA treated with MWA at our tertiary referral medical center was performed. Eight patients were treated between 2014 and 2019. Diagnosis of CCA was made based on histopathological studies of samples obtained by surgical resection or percutaneous liver biopsy. All procedures were performed under computed tomography (CT) guidance using a high-power single antenna MWA system. General anesthesia was used for all procedures. Patient medical history, procedural technical information, outcomes, and follow-up data were reviewed. Progression-free survival was estimated with a Kaplan-Meier curve. Results: A total of 25 tumors with an average size of 2.2 ± 1.7 cm (range 0.5-7.8) were treated with MWA. Our cohort consisted of eight patients (4 males and 4 females) with an average age of 69.3 ± 5.7 years (range 61-79). Three out of eight (3/8, 37.5%) patients were treated initially with surgical resection. NASH-related cirrhosis was documented in 3/8 (37.5%) patients, while 1/8 (12.5%) had alcoholic cirrhosis; the remaining 4 patients (4/8, 50%) did not have cirrhosis. All patients were discharged within 24 h after ablation. Average total follow-up time was 10.6 ± 11.8 months (range 0-41). The incomplete ablation rate and local recurrence rate were 4% (1/25 lesions) and 12% (3/25 lesions), respectively. Conclusion: In patients who do not qualify for surgical resection, MWA is a safe alternative therapy for the treatment of intrahepatic CCA.

Clinical and Survival Outcomes of Percutaneous Microwave Ablation for Intrahepatic Cholangiocarcinoma

Percutaneous Ultrasound-Guided Thermal Ablation for Intrahepatic Cholangiocarcinoma.

Efficacy analysis for percutaneous microwave ablation of intrahepatic cholangiocarcinoma

Contrast-enhanced Ultrasound Features Predict the Prognosis of Percutaneous Microwave Ablation of Intrahepatic Cholangiocarcinoma

Assessment of the Outcomes of Intrahepatic Cholangiocarcinoma after Ultrasound-Guided Percutaneous Microwave Ablation Based on Albumin–Bilirubin Grade

Percutaneous Microwave Ablation Combined With Simultaneous Transarterial Chemoembolization For The Treatment Of Advanced Intrahepatic Cholangiocarcinoma

Sonography-Guided Percutaneous Microwave Ablation of Intrahepatic Primary Cholangiocarcinoma

Clinical Outcome of Ultrasound-Guided Percutaneous Microwave Ablation on Colorectal Liver Metastases.

[Complications and Clinical Outcomes of Microwave Ablation for Liver Metastatic Cholangiocarcinoma after Bilioenteric Anastomosis].

Percutaneous Microwave Ablation for Hepatocellular Carcinoma Adjacent to Large Vessels: A Long-Term Follow-Up

Comparison of Cooled-Probe Microwave and Radiofrequency Ablation Treatment in Incipient Hepatocellular Carcinoma: A Phase Iii Randomized Controlled Trial with 6-Year Follow-Up

Us-Guided Percutaneous Microwave Ablation of Renal Cell Carcinoma: Intermediate-Term Results

Percutaneous microwave ablation for early-stage intrahepatic cholangiocarcinoma: A single-institutional cohort

Percutaneous Ultrasound-Guided Thermal Ablation of Intrahepatic Cholangiocarcinoma

Long-term Efficacy of Microwave Ablation in the Treatment of Subcapsular Hepatocellular Carcinomas of ≤3 Cm in Diameter: a Multicenter, Propensity Score-Matched Study

Comparison of Percutaneous Microwave Ablation and Surgical Resection for Hepatocellular Carcinoma in the Caudate Lobe

Microwave Ablation Vs. Surgical Resection for Treatment Naïve Hepatocellular Carcinoma Within the Milan Criteria: a Follow-Up of at Least 5 Years

Microwave ablation versus liver resection for primary intrahepatic cholangiocarcinoma within Milan criteria: a long-term multicenter cohort study

[Percutaneous Cooled-Tip Microwave Ablation under Ultrasound Guidance for Primary Liver Cancer: Analysis of Major Complications in 693 Patients].

[Curative effect of percutaneous microwave ablation therapy on hepatocellular carcinoma survival: a 15-year real-world study]

Survival Benefits Analyses of T1a Renal Cell Carcinoma Patients Treated with Microwave Ablation